سعر بادوزيثرو 200 مجم / 5 مل معلق 15 مل 2025

Azithromycin 200 mg/5 mL powder for oral suspension, 15 mL bottle; macrolide antibacterial (Badr Pharma, Egypt).

• Acute otitis media and community-acquired pneumoniaPopulation: Children 6 months and olderDailyMed (U.S. National Library of Medicine)
• Acute bacterial exacerbations of chronic bronchitis/COPD; acute bacterial sinusitis; community-acquired pneumonia (patients appropriate for oral therapy)Population: AdultsDailyMed (U.S. National Library of Medicine)
• Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative when first-line therapy cannot be usedPopulation: Adults and children 2 years and olderDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions are gastrointestinal: diarrhoea/loose stools, nausea, abdominal pain and vomiting; rash also reported (notably in children).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Postmarketing reports include arrhythmias, hepatitis/hepatic failure, hearing disturbances (hearing loss, tinnitus), taste/smell disturbance, interstitial nephritis, thrombocytopenia and serious skin reactions.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• History of cholestatic jaundice/hepatic dysfunction associated with prior azithromycin use.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Serious allergic and skin reactions (angioedema, anaphylaxis, AGEP, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS), sometimes fatal; symptoms may recur after symptomatic therapy is stopped. Discontinue if an allergic reaction occurs.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hepatotoxicity (hepatitis, cholestatic jaundice, hepatic necrosis/failure); stop immediately if signs of hepatitis occur. Infantile hypertrophic pyloric stenosis after use in neonates up to 42 days of life.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• QT prolongation and torsades de pointes: consider the risk in patients with known QT prolongation, bradyarrhythmias, uncompensated heart failure, uncorrected hypokalaemia/hypomagnesaemia, or those on class IA/III antiarrhythmics or other QT-prolonging drugs. Observational studies suggest a possible short-term increase in cardiovascular death.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• NelfinavirIncreases azithromycin serum concentrations; no dose adjustment, but monitor for liver enzyme abnormalities and hearing impairment.DailyMed (U.S. National Library of Medicine)
• Warfarin and other oral anticoagulantsPostmarketing reports of potentiated anticoagulant effect; monitor prothrombin time carefully.DailyMed (U.S. National Library of Medicine)
• Digoxin, colchicine, phenytoinInteractions seen with other macrolides; careful monitoring is advised when used with azithromycin.DailyMed (U.S. National Library of Medicine)

• Published data and decades of postmarketing experience have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Azithromycin is present in human milk; non-serious adverse reactions have been reported in breastfed infants. Monitor the infant for diarrhoea, vomiting or rash.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Azithromycin: Binds the 50S ribosomal subunit of susceptible bacteria and inhibits bacterial protein synthesis.